vs
Side-by-side financial comparison of SAUL CENTERS, INC. (BFS) and CorMedix Inc. (CRMD). Click either name above to swap in a different company.
CorMedix Inc. is the larger business by last-quarter revenue ($128.6M vs $75.1M, roughly 1.7× SAUL CENTERS, INC.).
Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
BFS vs CRMD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $128.6M |
| Net Profit | $6.5M | — |
| Gross Margin | — | 83.4% |
| Operating Margin | 65.4% | 46.0% |
| Net Margin | 8.7% | — |
| Revenue YoY | 10.6% | — |
| Net Profit YoY | -19.6% | — |
| EPS (diluted) | $0.15 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $128.6M | ||
| Q3 25 | $72.0M | $104.3M | ||
| Q2 25 | $70.8M | $39.7M | ||
| Q1 25 | $71.9M | $39.1M | ||
| Q4 24 | $67.9M | — | ||
| Q3 24 | $67.3M | — | ||
| Q2 24 | $66.9M | — | ||
| Q1 24 | $66.7M | — |
| Q4 25 | $6.5M | — | ||
| Q3 25 | $10.5M | $108.6M | ||
| Q2 25 | $10.7M | $19.8M | ||
| Q1 25 | $9.8M | $20.6M | ||
| Q4 24 | $8.1M | — | ||
| Q3 24 | $14.5M | — | ||
| Q2 24 | $14.4M | — | ||
| Q1 24 | $13.6M | — |
| Q4 25 | — | 83.4% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 95.3% | ||
| Q1 25 | — | 95.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | 73.6% | — | ||
| Q2 24 | 74.2% | — | ||
| Q1 24 | 72.8% | — |
| Q4 25 | 65.4% | 46.0% | ||
| Q3 25 | 69.1% | 49.2% | ||
| Q2 25 | 68.7% | 49.2% | ||
| Q1 25 | 66.5% | 51.5% | ||
| Q4 24 | 82.9% | — | ||
| Q3 24 | 72.8% | — | ||
| Q2 24 | 75.0% | — | ||
| Q1 24 | 72.4% | — |
| Q4 25 | 8.7% | — | ||
| Q3 25 | 14.6% | 104.1% | ||
| Q2 25 | 15.1% | 49.9% | ||
| Q1 25 | 13.6% | 52.8% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 21.5% | — | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | 20.4% | — |
| Q4 25 | $0.15 | $0.20 | ||
| Q3 25 | $0.32 | $1.26 | ||
| Q2 25 | $0.33 | $0.28 | ||
| Q1 25 | $0.29 | $0.30 | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $0.48 | — | ||
| Q2 24 | $0.48 | — | ||
| Q1 24 | $0.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.7M | $148.5M |
| Total DebtLower is stronger | $468.4M | — |
| Stockholders' EquityBook value | $307.8M | $405.3M |
| Total Assets | $2.2B | $826.1M |
| Debt / EquityLower = less leverage | 1.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.7M | $148.5M | ||
| Q3 25 | $11.8M | $55.7M | ||
| Q2 25 | $5.3M | $190.7M | ||
| Q1 25 | $6.5M | $77.5M | ||
| Q4 24 | $10.3M | — | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $6.9M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | $468.4M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $307.8M | $405.3M | ||
| Q3 25 | $316.6M | $374.1M | ||
| Q2 25 | $322.4M | $220.6M | ||
| Q1 25 | $328.4M | $114.9M | ||
| Q4 24 | $335.8M | — | ||
| Q3 24 | $341.8M | — | ||
| Q2 24 | $345.7M | — | ||
| Q1 24 | $347.1M | — |
| Q4 25 | $2.2B | $826.1M | ||
| Q3 25 | $2.2B | $750.9M | ||
| Q2 25 | $2.1B | $252.6M | ||
| Q1 25 | $2.1B | $149.6M | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | 1.52× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.8M | $94.5M |
| Free Cash FlowOCF − Capex | — | $92.7M |
| FCF MarginFCF / Revenue | — | 72.1% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | 15.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $172.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.8M | $94.5M | ||
| Q3 25 | $20.6M | $30.9M | ||
| Q2 25 | $26.6M | $30.0M | ||
| Q1 25 | $30.4M | $19.7M | ||
| Q4 24 | $121.2M | — | ||
| Q3 24 | $26.5M | — | ||
| Q2 24 | $32.1M | — | ||
| Q1 24 | $33.8M | — |
| Q4 25 | — | $92.7M | ||
| Q3 25 | — | $30.4M | ||
| Q2 25 | — | $30.0M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-28.3M | — | ||
| Q2 24 | $-12.5M | — | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | — | 72.1% | ||
| Q3 25 | — | 29.1% | ||
| Q2 25 | — | 75.4% | ||
| Q1 25 | — | 50.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -42.1% | — | ||
| Q2 24 | -18.7% | — | ||
| Q1 24 | -17.6% | — |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | 81.5% | — | ||
| Q2 24 | 66.7% | — | ||
| Q1 24 | 68.3% | — |
| Q4 25 | 15.35× | — | ||
| Q3 25 | 1.97× | 0.28× | ||
| Q2 25 | 2.48× | 1.51× | ||
| Q1 25 | 3.10× | 0.96× | ||
| Q4 24 | 14.98× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 2.22× | — | ||
| Q1 24 | 2.48× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFS
Segment breakdown not available.
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
